Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zecotek Photonics Inc ZMSPF

Zecotek Photonics Inc is in the business of research and development of photonics technologies. The company is focused on creating advanced materials and integrated optoelectronic devices for high-resolution medical imaging, optical precision surgery, and biopharmaceutical research. It operates in three divisions which include Imaging systems, Optronics systems, and 3D display systems with labs located in Canada, Korea, Russia, Singapore, and the U.S.A. The company develops products such as scintillation crystals, solid-state, photodetectors, positron emission tomography scanning components, lasers, and 3D display and 3D printing technologies. These products are used in sectors such as healthcare, scientific and industrial.


GREY:ZMSPF - Post by User

Comment by Pandoraon Apr 02, 2019 10:57pm
116 Views
Post# 29573876

RE:RE:RE:RE:RE:RE:Pandora & ZMS & Science

RE:RE:RE:RE:RE:RE:Pandora & ZMS & ScienceA couple of excerpts from the quarterly:

Going concern uncertainty:
These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which presumes that the Company will be able to realize assets and discharge its liabilities in the normal course of business for the foreseeable future. As at January31, 2019, the Company had limited operating revenue, a working capital deficiency of $3,473,442shareholders’ deficiency of $1,741,047, and negative operating cash flows of $3,637,663. The Company’s current revenue is not sufficient to sustain operations. These factors, among others, create significantdoubtas to the ability of the Company to continue as a going concern.

Subsequent Events:


ZIS offered a 2% equity interest in ZIS in exchange for USD 1.5million. The funds have been received but due to a declining share price, the Chinese investment group requested to renegotiate the investment and the parties agreed to make it a loan convertible to shares when the restructuring transaction is finalized. An additional USD 1.5 million was invested by the same investor during the quarter for an increase in equity interest. The terms have not been finalized to date.

Subsequent events
(continued):(e)Subsequent thequarter end, the Company expects to receive approval from Hamamatsu for the delivery of LFS scintillation boules produced by the LFS Scintillation Crystal Facility in Shanghai, representing thousands of LFS scintillation crystals. The deliveries cannot bebook as revenue until they are examined and qualified by Hamamatsu
<< Previous
Bullboard Posts
Next >>